510(k) K163367

GenetiSure Dx Postnatal Assay by Agilent Technologies, Inc. — Product Code PFX

K163367 is an FDA 510(k) premarket notification submitted by Agilent Technologies, Inc. for the device "GenetiSure Dx Postnatal Assay". The FDA issued a decision of Substantially Equivalent on Aug 11, 2017. The device falls under product code PFX (System, Microarray-Based, Genome-Wide, Postnatal Chromosomal Abnormality Detection), a Class II device regulated under 21 CFR 866.5920. Agilent Technologies, Inc. has 44 other 510(k) clearances on record.

Clearance details

Decision
SESE (Substantially Equivalent)
Decision Date
Aug 11, 2017
Date Received
Nov 30, 2016
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device classification

Device Name
System, Microarray-Based, Genome-Wide, Postnatal Chromosomal Abnormality Detection
Device Class
Class II
Regulation Number
866.5920
Review Panel
PA
Submission Type
510(k)

A microarray-based, genome-wide, postnatal chromosomal abnormality detection system is used to qualitatively detect constitutional gains and losses in chromosomal copy numbers across the human genome using microarray methods. It is intended as an aid in the postnatal diagnosis of developmental delay and/or intellectual disability (DD/ID), congenital anomalies, and dysmorphic features in conjunction with other clinical information currently used in postnatal diagnosis. It is not intended to be used for standalone diagnostic purposes, prenatal or pre-implantation testing or screening, population screening, or for the detection of, or screening for, acquired or somatic genetic aberrations.

Need the full FDA record for Agilent Technologies, Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: FDA 510(k) database entry for K163367. Report a data issue: hello@regdatalab.com.